Related Experiment Video
Updated: Aug 13, 2026
08:31
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
Current controversies in follicular lymphoma
1Division of Hematology & Oncology, Department of Medicine, Northwestern University, Feinberg School of Medicine and the Robert H. Lurie Comprehensive Cancer Center, 676 N. St. Clair Street, Suite 850, Chicago, IL 60611, USA. v-aurora@md.northwestern.edu
Blood Reviews
|January 18, 2006
Summary
Follicular lymphoma (FL) treatment involves managing relapses and progression. Combining rituximab with chemotherapy improves outcomes, while radioimmunotherapy is promising for relapsed or initial FL therapy.
Area of Science:
- Hematology
- Oncology
Background:
- Follicular lymphoma (FL) presents with initial treatment response, frequent relapses, and potential progression to diffuse large B-cell lymphoma.
- Current treatment decisions for FL are complex due to numerous effective therapeutic options.
Purpose of the Study:
- To review current and emerging therapeutic strategies for follicular lymphoma.
- To highlight the role of various treatment modalities, including chemotherapy, monoclonal antibodies, radioimmunotherapy, targeted agents, and stem cell transplantation.
Main Methods:
- Literature review of follicular lymphoma treatment options.
- Analysis of outcomes for different therapeutic approaches.
Main Results:
- Combination therapy with rituximab and conventional chemotherapy demonstrates improved outcomes over chemotherapy alone.
- Radioimmunotherapy shows promise as a first-line or relapsed disease treatment strategy.
- The role of stem cell transplantation in FL management requires further research.
Conclusions:
- Optimizing follicular lymphoma treatment requires considering various modalities, including novel agents and clinical trial participation.
- Personalized treatment strategies, potentially including "watch and wait" or involved field irradiation for select patients, are crucial.
